| Barchart Demo Center |
$1.5800
+0.1400 (+9.72%)
as of May 31, 2024
as of May 31, 2024
| Profile | |
|---|---|
| Ticker Symbol | AEON |
| Exchange | AMEX |
| Contact Information |
5 PARK PLAZA SUITE 1750 IRVINE, CA USA P: 949-354-6499 |
| CEO/President | Marc Forth |
| Earnings at a Glance | ||||
|---|---|---|---|---|
| Earnings | 03/31/24 -3.17 |
12/31/23 -1.03 |
09/30/23 0.61 |
06/30/23 -0.44 |
| Price Earnings Ratio | N/A | |||
| EPS Growth | 22.22 | |||
| Most Recent Earnings ($) | -3.1700 | |||
| Annual EPS ($) | N/A | |||
| Business Summary | |
|---|---|
| AEON Biopharma Inc. is a clinical-stage biopharmaceutical company. It focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions. AEON Biopharma Inc. formerly known as Priveterra Acquisition Corp. is based in IRVINE Calif. | |
| Industry/Sector | SIC-2834 Pharmaceutical Preparations Medical - Biomedical |